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This review focuses on the main therapeutic options to date 
available for PH of the adult and on emerging and potential thera-
pies under development.
TreaTmenT
The management of patients with PH has advanced rapidly over the 
last decade and the introduction of specific treatments especially 
for PAH has lead to an improved outcome for patients with this 
disease. A recent meta-analysis of 23 randomized controlled trial 
showed a 43% reduction in mortality and a 61% decrease in the 
rate of hospitalizations in patients with PAH treated with specific 
therapy in comparison with placebo (Galiè et al., 2009b). However, 
some patients still have a very poor prognosis and a rapid deteriora-
tion of their condition. For these reasons, early identification and 
treatment of PH are crucial because advanced disease may be less 
responsive to therapy.
Treatment begins with a baseline assessment of disease severity 
which is essential because the response to therapy will be meas-
ured as changes from baseline. Functional impairment and hemo-
dynamic derangement are the key determinants of disease severity: 
the former is determined by measuring the exercise capacity by 
the 6-min walking test and assessing the patient’s World Health 
Organization (WHO) functional class as reported in Table 2; the 
latter is based both on echocardiography that is useful to estimate 
DefiniTion anD classificaTion
Pulmonary hypertension (PH) is characterized by elevated pul-
monary arterial pressure and secondary right ventricular (RV) 
failure. It is a life-threatening condition with a poor prognosis if 
untreated. According to the most recent guidelines published jointly 
by the European Society of Cardiology (ESC) and the European 
Respiratory Society (ERS) PH is an hemodynamic and pathophysi-
ological state defined as an increase in mean pulmonary arterial 
pressure (PAPm) ≥25 mmHg at rest as assessed by right heart cath-
eterization (RHC; Galiè et al., 2009a). PH can be found in multiple 
clinical conditions and for this reason it is clinically classified into 
five groups, as shown in Table 1 (Simonneau et al., 2009). Patients 
in the first group are considered to have pulmonary arterial hyper-
tension (PAH), whereas patients in the remaining four groups are 
considered to have PH.
On the basis of hemodynamic parameters, PH is classified into 
two groups. Pre-capillary PH is characterized by PAPm ≥25 mmHg, 
pulmonary wedge pressure (PWP) ≤15 mmHg, cardiac output 
(CO) normal or reduced. It is typical of the group 1, i.e., PAH; 
group 3, i.e., PH due to lung diseases and/or hypoxemia; group 4, 
i.e., chronic thromboembolic PH (CTEPH); group 5, i.e., PH with 
unclear and/or multifactorial mechanisms. Post-capillary PH is 
characterized by PAPm ≥25 mmHg, PWP >15 mmHg, CO normal 
or reduced. It is typical of group 2, i.e., PH due to left heart disease.
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necessary to confirm that PH exists. However, RHC is often deferred 
until specific therapy is indicated because it is an invasive procedure.
The goal of the treatment recommended by the latest ESC/ERS 
guidelines is to obtain and maintain for the patient a “stable and 
  satisfactory” condition which is associated with a better prognosis (Galiè 
et al., 2009a). This condition is characterized by absence of clinical signs 
of RV failure, stable WHO functional class I or II, a 6-min walking 
distance >500 m depending on the individual patient, a peak oxygen 
consumption >15 mL/min/kg, normal or near-normal brain natriuretic 
peptide (BNP) and N-terminal fragment of pro-BNP (NT-proBNP) 
plasma  levels,  no  pericardial  effusion,  right  atrial  pressure  (RAP) 
<8 mmHg, and a cardiac index (CI) ≥2.5 L/min/m2 (Table 3).
Two levels of treatment can be identified: primary and specific 
therapy. Primary therapy is directed at the underlying cause of the 
PH. It also includes a supportive therapy which should be consid-
ered in all patients with PH. Specific therapy is directed at the PH 
itself and includes treatment with vasodilatators such as calcium 
channel blockers (CCBs) and with vasodilatator and pathogenetic 
drugs such as prostanoids, endothelin receptor antagonists and 
phosphodiesterase type-5 inhibitors. These drugs act in several 
pathogenetic mechanisms of the PH and are specific for PAH 
although they might be used also in the other groups of PH. A 
schematic diagram of the main mechanisms which trigger PAH 
and represent targets for pharmacological treatments is shown in 
Figure 1.
Table 1 | Clinical classification of pulmonary hypertension.
Group 1: Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic
1.2 Heritable (BMPR2, ALK1, endoglin,unknown)
1.3 Drugs and toxins induced 
1.4 Associated with (APAH): connective tissue diseases, HIV infection, Portal Hypertension, Congenital heart disease, Schistosomiasis, Chronic haemolytic 
    anemia
1.5 Persistent pulmonary hypertension of the newborn
Group 1’: Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
Group 2: Pulmonary hypertension due to left heart disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
Group 3: Pulmonary hypertension due to lung diseases and/or hypoxaemia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
Group 4: Chronic thromboembolic pulmonary hypertension
Group 5: Pulmonary hypertension with unclear and/or multifactorial mechanisms
5.1 Hematological disorders: myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell hystiocitosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure on dialysis
Table 2 | Functional classification of pulmonary hypertension according to World Health Organization (WHO).
CLASS I:   Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnoea 
or fatigue, chest pain, or near syncope.
CLASS II:   Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes 
undue dyspnoea or fatigue, chest pain, or near syncope.
CLASS III:   Patients with pulmonary hypertension resulting in marked limitation of physical activity. Less than ordinary activity causes undue dyspnoea or 
fatigue, chest pain, or near syncope.
CLASS IV:   Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right 
heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
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Oxygen supplementation is of fundamental importance in all 
patients with arterial hypoxemia. The indication to the oxygen 
therapy is generally set at a value of arterial pressure of oxygen 
(PaO2) less than 60 mmHg. Continuous oxygen administration 
represents the cornerstone of the therapy in patients with group 3 
PH but it should also be considered for all patients with PH plus 
hypoxemia at rest, during exercise and/or at night. Indeed, oxy-
gen is the only treatment with proven mortality benefit in some 
patients with group 3 PH as shown by two large trials which stud-
ied patients with chronic obstructive pulmonary disease (COPD), 
the most common cause of group 3 PH (NOTT, 1980; MRC, 
1981). On the contrary, there are no randomized data to   suggest 
Primary TheraPy
It is warranted in patients with groups 2 and 3 who have PH sec-
ondary to left heart disease and lung diseases, respectively, and in 
patients with group 5 who have PH secondary to hematologic, 
systemic or metabolic disorders. In patients with group 4 who have 
PH due to thromboembolic occlusion of the proximal or distal 
pulmonary vasculature, anticoagulation is primary medical ther-
apy, whereas surgical thromboendarterectomy is primary surgical 
therapy for selected patients with thromboembolic obstruction of 
the proximal pulmonary arteries.
Supportive  therapy  which  should  be  considered  in  all 
patients  with  PH  includes  oxygen  supplementation,  diuretics, 
  anticoagulation and exercise.
Table 3 | Parameters with established importance for assessing disease severity, stability, and prognosis.
Better prognosis  Determinants of prognosis  Worse prognosis
No  Clinical evidence of RV failure  Yes
Slow  Rare of progression of symptoms  Rapid
I, II  WHO functional class  IV
Longer  6-min walking distance  Shorter
Peak oxygen consumption > 15 mL/min/kg  Cardiopulmonary exercise testing  Peak oxygen consumption < 12 mL/min/kg
Normal or near-normal  BNP/NT-pro-BNP plasma levels  Very elevated
No pericardial effusion  Echocardiographic findings  Pericardial effusion
RAP < 8 mmHg and CI ≥ 2.5 L/min/m2  Hemodynamics  RAP > 15 mmHg or CI < 2.0 L/min/m2
RV, right ventricular; BNP/NT-pro-BNP , brain natriuretic peptide/N-terminal fragment of pro-BNP; RAP , right atrial pressure; CI, cardiac index.
FIGure 1 | Mechanisms which trigger pulmonary arterial hypertension 
(PAH) as targets for pharmacological treatments. cAMP , cyclic adenosine 
monophosphate; cGMP , cyclic guanosine monophosphate; ET, endothelin; ETA, 
endothelin receptor A; ETB, endothelin receptor B; PDE5, phosphodiesterase 
type-5; PgI2, prostaglandin I2. Reproduced with permission from Humbert et al. 
(2004a) and Boutet et al. (2008).
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It is directed at the PH itself and is considered for patients who have 
evidence of persistent PH and a WHO functional class II, III, or IV 
despite adequate primary therapy (Badesch et al., 2007; Barst et al., 
2009). Specific therapy is often needed for patients with group 1 PH, 
because there are not effective primary therapies for these patients.
Patients with PH who are selected for specific therapy should 
undergo an invasive hemodynamic assessment, i.e., RHC, prior to 
the initiation of treatment. It is recommended that patients with 
group 1 PH also undergo a vasoreactivity test with intravenous 
adenosine, intravenous epoprostenol, or inhaled nitric oxide (NO, 
Barst et al., 2009). Patients with a positive vasoreactivity test can 
be given a trial of oral CCB therapy. In contrast, patients with 
a negative vasoreactivity test require therapy with a prostanoid, 
endothelin receptor antagonist, or phosphodiesterase type-5 inhibi-
tor. Combination specific therapy may be appropriate in refractory 
cases, although data are limited. Some patients are refractory to all 
medical interventions. In such cases, lung transplantation or crea-
tion of a right to left shunt by atrial septostomy may be considered 
(Keogh et al., 2009). The main pharmacological characteristics of 
the specific drugs are reported in Table 4.
calcium channel blockers
The rationale to use vasodilatators such as CCBs is that vasocon-
striction and smooth muscle cell hypertrophy contribute to the 
pathogenesis of PH. However, it has been recognized that these 
drugs are of benefit only in a small number of patients with PAH 
who demonstrate a positive response to the vasoreactivity test. 
These patients can achieve prolonged survival, sustained functional 
improvement and hemodynamic improvement by taking nifed-
ipine or diltiazem (Rich et al., 1992; Humbert et al., 2004a; Sitbon 
et al., 2005). The daily doses of these drugs that have shown efficacy 
in PAH are relatively high, 120–240 mg for nifedipine, 240–720 mg 
for diltiazem. CCB therapy can be initiated with either long-acting 
nifedipine (30 mg/day) or diltiazem (120 mg/day), then increased to 
the maximal tolerated dose. Sustained release preparations of both 
that long-term oxygen therapy is beneficial in patients with PAH, 
although oxygen administration has been demonstrated to reduce 
the pulmonary vascular resistance in these patients (Galiè et al., 
2009a). Oxygen is generally administered via nasal prongs or 
Venturi masks at a flow rate or concentration as to maintain 
saturation above 90%.
DiureTics
Diuretics are used to treat fluid retention due to PH and to 
reduce hepatic congestion and peripheral edema. Moreover, diu-
resis can prevent a distended right ventricle from impending 
left ventricular filling. Diuretics are especially useful in patients 
with groups 2 and 3 PH. Although there are no randomized 
controlled trials of diuretics in PAH, clinical experience shows 
symptomatic benefits also in patients with group 1 PH when a 
decompensated right heart failure occurs. However, they should 
be administered with caution to avoid decreased CO (due to 
decreased right and/or left ventricular preload), arrhythmias 
induced by hypokalemia, and metabolic alkalosis. The most 
commonly used loop diuretic is furosemide, usually at a start-
ing dose of 20–40 mg daily.
anTicoagulaTion
Patients with PH are at increased risk for intrapulmonary throm-
bosis and thromboembolism, due to sluggish pulmonary blood 
flow, dilated right heart chambers, venous stasis, and a sedentary 
lifestyle. These risk factors and the consideration that even a small 
thrombus can produce hemodynamic deterioration in a patient 
with a compromised pulmonary vascular bed that is unable to 
dilate or recruit unused vasculature, represent the rationale for 
oral anticoagulation in PH. It is generally accepted that antico-
agulation is indicated in patients with idiopathic PAH, hereditary 
PAH and drug-induced PAH (Barst et al., 2009; Galiè et al., 2009a; 
McLaughlin et al., 2009), or group 4 PH. However, most of the 
evidence comes from observational studies of patients with idi-
opathic PAH (Kawut et al., 2005; Barst et al., 2009). In a systematic 
review of seven observational studies that evaluated the effect of 
warfarin in patients with group 1 PH, five studies found a mortal-
ity benefit (Johnson et al., 2006). In patients with other groups of 
PH the potential benefits of anticoagulation should be weighed 
against the risk of bleeding.
The anticoagulant of choice is warfarin, with a therapeutic goal 
of an International Normalized Ratio (INR) of approximately two.
exercise
Exercise training appears to be beneficial for patients with PH 
(Mereles et al., 2006; de Man et al., 2009). A randomized control-
led trial has demonstrated an improvement in exercise capacity in 
patients with PAH who took part in a training program (Mereles 
et al., 2006). Exercise training improved the WHO functional class 
and peak oxygen consumption although it didn’t improve hemo-
dynamic abnormalities (Mereles et al., 2006). Moreover, there 
is growing evidence supporting loss of peripheral muscle mass 
in patients with advanced PAH, and this may be corrected by a 
defined rehabilitation program (Galiè et al., 2009a). Thus, skel-
etal muscle training may play a role in the treatment of patients 
with PH.
Table 4 | Main pharmacological characteristics of the drugs used in the 
specific therapy.
Drug  route of administration  Dosage
CALCIuM CHAnneL BLOCKerS
Nifedipine  Oral  120–240 mg/day
Diltiazem  Oral  240–720 mg/day
Amlodipine  Oral  20 mg/day
PrOSTAnOIDS
Epoprostenol  Intravenous  1–40 ng/kg/min
Treprostinil  Subcutaneous/Intravenous  2–80 ng/kg/min
Iloprost  Inhalation  2.5–5 mcg, 6–9 time/day
enDOTHeLIn reCePTOr AnTAGOnISTS
Bosentan  Oral  62.5–125 mg, 2 time/day
Ambrisentan  Oral  5–10 mg/day
PHOSPHODIeSTerASe TyPe-5 InHIBITOrS
Sildenafil  Oral  20 mg, 3 time/day
Tadalafil  Oral  5–40 mg/day
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walking test) was greater in the iloprost group compared to the 
placebo group. Overall, inhaled iloprost is well tolerated with flush-
ing and cough being the most frequent side effects. Inhaled iloprost 
is approved by the FDA for PAH patients in WHO functional class 
III and IV.
Beraprost is the first orally active prostacyclin analog. A rand-
omized controlled trial showed that this compound improved the 
exercise capacity in patients with PAH. However this improvement 
persisted only up to 3–6 months and there were no hemodynamic 
benefits (Galiè et al., 2002).
enDoThelin recePTor anTagonisTs
Endothelin-1  is  a  potent  vasoconstrictor  and  smooth  muscle 
mitogen. High concentrations of endothelin-1 have been recorded 
in the lungs of patients with PAH (Channick et al., 2004). Two 
distinct  receptors  with  different  characteristics  are  present  in 
the pulmonary vascular smooth muscle cells and, in part, in the 
endothelial cells: endothelin-A and endothelin-B receptors. Despite 
potential differences in receptor activity, the efficacy in PAH of 
the dual endothelin-A and B receptor antagonist drugs and of 
selective endothelin receptor antagonist compounds appears to 
be comparable.
Bosentan is an oral active dual endothelin-A and B receptor 
antagonist. It has been evaluated in several randomized controlled 
trials that have shown improvement in exercise capacity, hemody-
namic variables and time to clinical worsening in patients with PAH 
(Rubin et al., 2002; Galiè et al., 2006, 2008a). The major advantage 
of bosentan is its oral administration. It appears to be effective in 
group 1 PH patients both in WHO functional class III or IV and 
in WHO functional class II. The initial dose is 62.5 mg twice daily 
and uptitrated to 125 mg twice daily after 4 weeks. Increases in 
hepatic aminotransferases occurred in about 10% of the patients 
but were found to be dose dependent and reversible after discon-
tinuation of the drug.
Sitaxentan  is  a  selective  orally  active  endothelin-A  receptor 
antagonist which has been assessed in two randomized control-
led trials on PAH patients with WHO functional class II and III 
(Barst et al., 2004, 2006b). The studies demonstrated the efficacy 
of sitaxentan in improving exercise capacity and hemodynamics. 
The commonly used dose is 100 mg once daily. However, sitaxentan 
has been very recently withdrawn from the market worldwide after 
two cases of fatal liver injury and all ongoing clinical trials have 
also been discontinued.
Ambrisentan  is  another  selective  orally  active   endothelin-A 
receptor antagonist. It has shown to improve exercise tolerance, 
WHO functional class, hemodynamics and quality of life in patients 
with PAH with a durability of the effects for at least 1 year (Galiè 
et al., 2008b; Oudiz et al., 2009). Ambrisentan has been approved 
for the treatment of patients in WHO functional class II and III at 
a dose of 5 mg once daily which can be increased to 10 mg once 
daily. As reported above, the main adverse effect of the endothe-
lin receptor antagonists is hepatotoxicity, which appears to be 
more severe at higher doses. According to one observational study 
ambrisentan may be a safe and effective alternative for patients who 
previously discontinued bosentan or sitaxsentan due to abnor-
mal liver function test results (McGoon et al., 2009),   suggesting 
nifedipine and diltiazem are recommended because they   minimize 
the adverse effects of therapy, especially systemic hypotension. 
Amlodipine, a long-acting dihydropyridine, is a useful alternative 
at a dosage up to 20 mg/day. Patients who respond to CCB therapy 
should be reassessed after 3–6 months of treatment.
ProsTanoiDs
Prostanoids are prostacyclin analogs. Prostacyclin is produced 
by the endothelial cells, induces vasodilatation and is a powerful 
platelet aggregation inhibitor. Its synthesis is reduced in patients 
with PAH (Galiè et al., 2003). Prostanoid formulations used to 
treat PH include epoprostenol, treprostinil, and iloprost. All have 
the limitation of a short half-life and a heterogeneous response 
to therapy.
Epoprostenol used intravenous improves hemodynamic param-
eters and functional capacity in patients with PAH (Rubin et al., 
1990; Barst et al., 1996; Shapiro et al., 1997; Higenbottam et al., 
1998) and is the only treatment shown to improve survival in idi-
opathic PAH in a randomized trial (Barst et al., 1996). The main 
limitation of its use is that it has a short half-life (3–5 min) and is 
stable for only 8 h. Therefore it needs to be administered continu-
ously by an infusion pump and a permanently implanted central 
venous catheter. It is usually initiated at doses of 2–4 ng/kg/min and 
increased by 1–2 ng/kg/min every 1 to 2 days as tolerated. The opti-
mal dose varies between 20 and 40 ng/kg/min. Side effects include 
both diarrhea, arthralgias, flushing, headache and effects related 
to the delivery system such as thrombosis, local site infection, sep-
sis. For these side effects and for its administration disadvantages, 
epoprostenol perfusion cannot be considered an ideal treatment 
and this drug is generally used as first-line agent only in patients 
with severe disease (i.e., WHO functional class IV).
Treprostinil is a epoprostenol analog with a longer half-life 
(58–80 min) which can be given intravenously or subcutaneously 
although subcutaneous administration, that is accomplished by a 
microinfusion pump and a small subcutaneous catheter, frequently 
induces local side effects such as severe pain. It is available also 
for aerosol administration. Inhaled treprostinil has recently been 
approved for patients with group 1 PH who are WHO functional 
class III. Several randomized controlled trial have been shown that 
treprostinil improves hemodynamic parameters, symptoms, and 
exercise capacity (Barst et al., 2006a; Tapson et al., 2006; Benza et al., 
2008). Treatment with subcutaneous treprostinil is initiated at a 
dose of 1–2 ng/kg/min with doses increasing at a rate limited by 
side effects (flushing, headache, local pain). The optimal dose varies 
between 20 and 80 ng/kg/min. The use of intravenous treprostinil is 
approved by the US Food and Drug Administration (FDA) in WHO 
functional class II, III, and IV PAH patients in whom subcutaneous 
infusion in not tolerated.
Iloprost is a prostacyclin analog available for aerosol administra-
tion. Inhaled iloprost has theoretical advantages in targeting the 
lung vasculature and not require intravenous administration. The 
main disadvantages is the need for frequent administration (six 
to nine time per day) due to its short half-life. Iloprost has been 
evaluated in a randomized controlled trial in which patients with 
group 1 and 4 PH who were in WHO functional class III and IV, 
inhaled iloprost (median 30 mcg daily) or placebo for 12 weeks 
(Olschewski et al., 2002). The primary endpoint (improvement 
Fuso et al.  Treatment of pulmonary hypertension
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The addition of inhaled treprostinil may improve the exercise 
capacity and quality of life of patients with persistent symptoms 
despite bosentan or sildenafil therapy. In a randomized controlled 
trial, 235 patients with group 1 PH, a WHO functional class III 
or IV, and a 6-min walking distance of only 200–450 m despite 
bosentan or sildenafil therapy were randomly assigned to receive 
either inhaled treprostinil or placebo for 12 weeks (McLaughlin 
et al., 2010). The treprostinil group had a larger improvement in 
their 6-min walking distance and quality of life, but there were no 
differences in the time to clinical worsening, dyspnea, or WHO 
functional class.
Sildenafil added to epoprostenol
The  addition  of  sildenafil  to  long-term  epoprostenol  therapy 
improves clinical outcomes. A trial randomly assigned 267 patients 
with group 1 PH who were receiving epoprostenol to have sildenafil 
or placebo added for 16 weeks (Simonneau et al., 2008). Sildenafil 
improved hemodynamic parameters, exercise capacity, quality of 
life, and time to clinical worsening, compared to placebo but there 
was no difference in dyspnea.
Sildenafil added to bosentan
A prospective cohort study followed 25 patients with group 1 
PH who were initially treated with bosentan monotherapy, but 
developed clinical deterioration and had sildenafil added (Mathai 
et al., 2007). Clinical improvement occurred after the addition of 
sildenafil, as measured by symptoms, exercise capacity, and WHO 
functional class. Improvement was more frequent and of greater 
magnitude in patients with idiopathic PAH, compared to patients 
with scleroderma-associated PAH.
Sildenafil added to iloprost
The combination of iloprost plus sildenafil may improve outcomes 
compared to either agent alone (Ghofrani et al., 2002a, 2003).
There are many open questions regarding combination therapy, 
including the choice of combination agents, the optimal timing 
(initial combination in naive patients or sequential combination 
according to the response to the first drug), when to switch, and 
when to combine. Combination therapy of established PAH drugs 
is recommended for patients not responding adequately to mono-
therapy, but combination therapy should be instituted by expert 
centers only. Whether the response to monotherapy is sufficient 
or not can only be decided on an individual basis. This is judged 
in an individual patient who, despite monotherapy and optimized 
background treatment, has an inadequate clinical response (Galiè 
et al., 2009a).
non-meDical TreaTmenT
Therapeutic options in PH other than medical therapies are mainly 
represented by surgical treatment which should be considered only 
in selected patients.
aTrial sePTosTomy
The  creation  of  a  right-to-left  shunt  by  atrial  septostomy 
can  decompress  the  right  heart  chambers  and  increase  left 
ventricular  preload.  The  goal  is  to  increase  systemic  blood 
the    hepatotoxicity  may  differ  among  the  endothelin    receptor 
  antagonists. Liver function tests should be closely monitored dur-
ing therapy and endothelin receptor antagonists should be avoided 
in patients with moderate or severe hepatic dysfunction.
PhosPhoDiesTerase TyPe-5 inhibiTors
The  pulmonary  vasculature  contains  substantial  amounts  of 
phosphodiesterase type-5, an enzyme that specifically contrib-
utes  to  cyclic  guanosine  monophosphate  (cGMP)  breakdown, 
thus decreasing smooth muscle cell capacity for vasodilatation. 
Inhibition of the cGMP degrading enzyme results in vasodilata-
tion through the increase of NO which is a potent vasodilatator.
Sildenafil  is  an  orally  active  inhibitor  of  phosphodiesterase 
type-5 that improves pulmonary hemodynamics, symptoms, and 
exercise capacity in patients with group 1 PH (Galiè et al., 2005; 
Pepke-Zaba et al., 2008). However its effect on mortality has not 
been adequately evaluated. Indeed in a randomized controlled trial 
patients treated with sildenafil demonstrated a significant improve-
ment in hemodynamics and 6-min walking distance in comparison 
with patients treated with placebo (Galiè et al., 2005). This ben-
eficial effects persisted during 1 year of follow-up but mortality 
was not reported (Galiè et al., 2005). The drug is approved for 
patients with WHO functional class II and III at a dose of 20 mg 
three times daily. However the durability of effect up to 1 year has 
been demonstrated only with the dose of 80 mg three times daily. 
The side effects of sildenafil are mainly related to vasodilatation 
(flushing, headache). It should be used with caution in patients 
with arterial hypotension.
Tadalafil is a once-daily dispensed phosphodiesterase type-5 
inhibitor currently approved for the treatment of erectile dys-
function which appears to improve outcomes in patients with 
group 1 PH. A randomized clinical trial has shown favora-
ble results on exercise capacity, hemodynamics, and time to 
clinical worsening in patients treated with the largest dose of 
tadalafil (40 mg daily) compared to patients receiving placebo 
(Galiè et al., 2009c).
combinaTion TheraPy
It has been proposed that combining pharmacologic agents with 
different mechanisms of action may produce an additive effect or 
may induce the same effect at lower doses of each agent. Clinical 
studies have begun to evaluate combination therapy.
Bosentan added to either epoprostenol or treprostinil
Limited experience suggests that bosentan can be used safely and 
effectively  added  to  epoprostenol  or  subcutaneous  treprostinil 
therapy (Humbert et al., 2004b; Benza et al., 2008).
Bosentan plus iloprost
The effect of combining bosentan with iloprost is less clear. Early 
observational studies suggested that the combination was both safe 
and effective when bosentan was added to preexisting inhaled ilo-
prost therapy (Hoeper et al., 2003). However, a subsequent trial 
that randomly assigned 40 patients with idiopathic PAH to receive 
bosentan alone or bosentan plus iloprost for 12 weeks, demon-
strated no difference in the 6-min walking distance, the trial’s 
  primary endpoint (Hoeper et al., 2006a).
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This treatment is specifically indicated for patients with group 4 PH, 
i.e., patients with CTEPH. CTEPH is one of the most prevalent forms 
of PH. Nevertheless its overall prevalence is very difficult to determine 
since not all patients have a history of acute pulmonary embolism, acute 
embolism may be clinically silent, and finally CTEPH may develop in 
the absence of previous pulmonary embolism (Hoeper et al., 2006b; 
Galiè et al., 2009a). In these cases the disease is probably initiated by 
thrombotic or inflammatory lesions in the pulmonary vasculature 
and then a process of pulmonary vascular remodeling is started which 
self-perpetuates the progression of PH (Rubin et al., 2006).
Oral anticoagulation is the most important medical therapy for 
these patients but pulmonary thromboendarterectomy remains the 
treatment of choice as it is a potentially curative option. However 
the surgical approach is possible only in selected patients (Dartevelle 
et al., 2004). Indeed, the decision to proceed to pulmonary throm-
boendarterectomy in patients suffering from CTEPH is based upon 
both objective and subjective factors, which are carefully defined 
during the preoperative evaluation (Moser et al., 1992; Dunning and 
McNeil, 1999). The first and most important criterion for potential 
surgical intervention is the accessibility of the thrombi, as defined by 
angiography. Present surgical techniques allow removal of chronic 
thrombi whose proximal location extends to the main, lobar, and 
segmental arteries. The second criterion involves the presence of a sig-
nificant hemodynamic or ventilatory impairment as a consequence 
of the chronic thromboembolic pulmonary vascular obstruction. 
The third criterion is the absence of co-morbid conditions.
Approximately 4,000 operations of pulmonary thromboendarterec-
tomy have been performed worldwide and the results are excellent with 
post-operative mortality rates ranging from <5 to 10% (Keogh et al., 
2009). A significant trend of improved survival with increasing levels 
of experience of the surgical team has been shown by Mayer (2010) 
who reported an early mortality of 10.9% in 210 operations performed 
from 1994 to 2003 and of 5.2% in 210 operations performed from 
2003 to 2009. Other observational studies confirmed that perioperative 
mortality decreased in the last decades (Jamieson et al., 2003; Condliffe 
et al., 2008). In one study of 500 consecutive patients who underwent 
thromboendarterectomy, perioperative mortality was 16% before 1990, 
7% between 1990 and 1999, and 4% between 1998 and 2002 (Jamieson 
et al., 2003). Long-term mortality is low among patients who survive 
the 3-month post-operative period. In an observational study that fol-
lowed 137 such patients, only six (4%) died during the 4-year follow-up 
period (Corsico et al., 2008). A similar study demonstrated 1- and 3-year 
mortality rates of 1 and 6%, respectively, among patients who survived 
the post-operative period (Condliffe et al., 2008).
TreaTmenT algoriThms
Different therapeutic approaches can be considered in the man-
agement of patients with PH. Therapy can be established on the 
basis of both the clinical classification and the functional class. It is 
also possible to adopt a goal-oriented therapy in which the timing 
of treatment escalation is determined by inadequate response to 
known prognostic indicators.
TheraPy accorDing To clinical classificaTion
There  are  special  considerations  and  different  therapeutic 
  indications for each group of PH, as shown in Table 5.
flow by   by-passing the pulmonary vascular obstruction. The 
  consequent arterial desaturation that follows the procedure is 
offset by increased CO and augmentation of systemic oxygen 
delivery (Reichenberger et al., 2003). Atrial septostomy may be 
considered in individuals with refractory severe PAH and right 
heart failure, despite aggressive specific therapy and maximal 
diuretic therapy (Doyle et al., 2004). It may also be considered 
in patients who have signs of impaired systemic blood flow 
(such as syncope) due to reduced left heart filling. Stepwise 
balloon  dilatation  is  the  procedure  of  choice  (Keogh  et  al., 
2009). However, procedure-related mortality may be as high as 
15–20% (Sandoval et al., 2001; Reichenberger et al., 2003) and 
it is difficult to predict which patients will benefit and which 
will deteriorate after this therapy.
TransPlanTaTion
The advent of disease-specific therapy for severe PAH has reduced 
patient referral for lung transplant programs (Keogh et al., 2009). 
However, the long-term outcomes of medically treated patients 
remains uncertain and transplantation should remain an impor-
tant option for those who fail on such therapy. Studies indicate 
that up to 25% of patients with idiopathic PAH may fail to improve 
on disease-specific therapy and the prognosis of patients who 
remain in WHO functional class III or IV is poor (McLaughlin 
et al., 2002; Sitbon et al., 2002). Thus transplantation is considered 
by some to be the final effective treatment for selected patients 
with idiopathic PAH. Bilateral lung or heart–lung transplanta-
tion is the procedure of choice (Keogh et al., 2009). The 3 year 
survival of patients who had a lung or heart–lung transplant for 
idiopathic PAH is approximately 50% (Doyle et al., 2004; Trulock 
et al., 2007). The timing of transplantation is critical. Guidelines 
for when to refer a patient for transplant evaluation are as fol-
lows (Orens et al., 2006): WHO functional class III or IV; mean 
right atrial pressure > 10 mmHg; PAPm > 50 mmHg; CI < 2.5 L/
min/m2; failure to improve functionally despite medical therapy; 
rapidly progressive disease.
Transplant organizations and organ allocation policies are influ-
enced by medical, ethical, geographical, and political factors, and 
systems vary from country to country. In the United States, since 
May 2005, the order of patients on the waiting list for lung trans-
plantation has been based on a Lung Allocation Score (LAS) that 
was developed to address high waiting list mortality and progres-
sively earlier placement of patients on the waiting list. The three 
main objectives of LAS include: (1) reducing the number of deaths 
on the lung transplant waiting list; (2) increasing transplant benefit 
for lung recipients; (3) ensuring the efficient and equitable alloca-
tion of lungs to active transplant candidates. The LAS system works 
by assigning a score ranging from 0 to 100 to all candidates older 
than age 12. It is a weighted combination of the predicted risk of 
death during the following year on the waiting list and the predicted 
likelihood of survival during the first year following transplantation 
(Davis and Garrity, 2007). Higher scores represent higher urgency 
and greater potential transplant benefit. In the 2 years following 
implementation of the LAS system, wait-list times decreased and 
the mean LAS score of transplant recipients increased, consistent 
with a greater urgency for transplantation; the total number of 
patients transplanted also increased (Iribarne et al., 2009).
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not approved by the US FDA for patients with group 3 PH and 
several guideline panels recommend against its use in this popu-
lation, except in the context of a clinical trial (Galiè et al., 2009a; 
Hoeper et al., 2009). Despite this, it is occasionally considered for 
patients who remain WHO functional class III or IV despite cor-
rection of hypoxemia and optimization of therapy of the underly-
ing disease, especially if the severity of the PH is out of proportion 
to the severity of the parenchymal lung disease. Specific therapy for 
patients with group 3 PH should administered cautiously due to its 
potential to worsen ventilation-perfusion mismatch and increase 
hypoxemia (Ghofrani et al., 2002b; Blanco et al., 2010).
Group 4
Anticoagulation is primary medical therapy for patients with group 
4 PH and its value is based on the clinical evidence that antico-
agulation prevents recurrent pulmonary embolism. Nevertheless, 
data suggesting that anticoagulation is beneficial in patients with 
CTEPH are lacking. Surgical thromboendarterectomy is primary 
surgical therapy for selected patients (Keogh et al., 2009). Specific 
therapy can be considered for patients with group 4 PH who 
remain WHO functional class III or IV even after anticoagula-
tion or thromboendarterectomy. Pharmacologic therapy can also 
act as a bridge to surgical intervention or can be used in patients 
with inoperable disease and those with persistent or recurrent PH 
after pulmonary thromboendarterectomy (Piazza and Goldhaber, 
2011). Epoprostenol, and sildenafil have been tested in patients 
with CTEPH with some beneficial hemodynamic effects (Nagaya 
et al., 2003; Suntharalingam et al., 2008). The efficacy of bosentan 
has been investigated in a randomized controlled trial (Jais et al., 
2008). Bosentan significantly improved the pulmonary vascular 
resistance and CI, compared to placebo. However, exercise capacity 
(measured by a 6-min walking test) did not improve.
Group 5
Primary therapy, directed at the underlying cause, represents the 
main treatment in patients of this group. Small studies have addressed 
the role of specific therapy for patients with PH related to sarcoidosis. 
One series of eight patients described a favorable response to intra-
venous epoprostenol in most patients (Fisher et al., 2006).
TheraPy accorDing To funcTional class
A therapeutic approach based on severity of the disease is actu-
ally recommended in patients with PAH as shown in Figure 2 
(Galiè et al., 2009a).
Functional class I
Considering the mild functional limitation, there is not a clear 
indication to treatment in these patients except for primary therapy 
if there is an associated disease causing PAH. In patients with idi-
opathic PAH and a positive response to the vasoreactivity test, CCBs 
may be effective. Supportive therapy is rarely indicated.
Functional class II, III, IV
These patients should to be evaluated for specific therapy. In 
addition, the need for oxygen, diuretic, and anticoagulant ther-
apy should be assessed. All patients selected for specific therapy 
Group 1
Treatment in patients of this group is based essentially on specific 
therapy because there are no effective primary therapies especially 
for patients with idiopathic PAH. Primary therapy is possible only 
in PAH associated with other diseases. Supportive therapy with 
oxygen to correct hypoxemia and diuretics to treat fluid retention, 
may be used, as needed. It is generally accepted that anticoagulation 
is indicated in patients with idiopathic PAH (Barst et al., 2009; Galiè 
et al., 2009a; McLaughlin et al., 2009).
Group 2
Primary therapy is the main treatment in patients of this group 
and consists in the treatment of the underlying heart disease. 
Specific therapy should be avoided in most of these patients 
because it may be harmful, as demonstrated in a randomized 
trial that showed the detrimental impact of epoprostenol on mor-
tality of patients with PH and severe left ventricular dysfunction 
(McLaughlin et al., 2009). A possible explanation of this effect 
includes the inability of a compromised left heart to handle the 
increased flow across a newly dilated pulmonary vascular bed 
(Badesch et al., 2009).
Group 3
Primary therapy represents the main treatment also for patients 
of  this  group.  Indeed,  any  treatment  able  to  delay  the  natu-
ral progression of pulmonary disease and to reduce the loss of 
pulmonary function seems to have a favorable impact on PH. 
Moreover, the correction of hypoxemia with supplemental oxy-
gen plays an   important role in these patients. Continuous oxy-
gen therapy improves survival in patients with COPD and PaO2 
below 55 mmHg, despite seemingly mild effects on pulmonary 
Table 5 | Therapy according to the clinical classification.
Group (clinical classification)  Therapeutic strategy
1. Pulmonary arterial hypertension  Specific therapy (idiopathic 
  and heritable forms)
  Primary therapy (forms associated 
  to other diseases)
  Supportive therapy (oral 
  anticoagulant, oxygen, diuretics)
  Surgical therapy (lung transplantation, 
  atrial septostomy)
2. Pulmonary hypertension  Primary therapy 
due to left heart disease  Supportive therapy (diuretics, oxygen)
3. Pulmonary hypertension due to  Primary therapy 
lung diseases and/or hypoxaemia  Supportive therapy (diuretics, oxygen)
  Specific therapy (in selected patients)
  Surgical therapy (lung transplantation)
4. Chronic thromboembolic  Supportive therapy (oral anticoagulant) 
pulmonary hypertension  Surgical therapy 
  (thromboendoarterectomy)
  Specific therapy (in selected patients)
5. PH with unclear and/or  Primary therapy 
multifactorial mechanisms  Supportive therapy (oxygen)
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6-min walking distance and some hemodynamic parameters 
representing alternatives (Sitbon and Galiè, 2010). The goal-
oriented treatment algorithm proposed by Hoeper et al. (2005) 
identifies 6-min walking distance, peak oxygen consumption, 
and peak systolic blood pressure as prognostic indicators and set 
values for each of them that act as goals (Figure 3). According 
to this algorithm, patients were started on first-line bosentan 
monotherapy: if patients met the three treatment goals dur-
ing follow-up, monotherapy was continued but, if a goal was 
not met, additional therapy was added. The authors reported 
that after 3 years of follow-up survival improved by using this 
goal-oriented therapy (80 versus 63% of historical controls; 
Hoeper et al., 2005).
new classes of Drugs in DeveloPmenT
Despite the progress in the treatment of PH, the functional limita-
tion and the survival of these patients remain unsatisfactory and 
there is no cure for PAH. Therefore the search for an “ideal” treat-
ment still goes on, triggered by research aiming to identify new 
molecular pathways which are important in both initiating and 
aggravating the disease process.
The following is a brief presentation of new classes of drugs tested 
in experimental models and already subject to ongoing clinical trials.
rho-kinase inhibiTors: fasuDil
Rho-kinase plays an important role in PAH: it enhances the con-
traction of the vascular smooth muscle cells through inhibition 
of myosin phosphatase and activation of its downstream effec-
tors. On the contrary, an over expression of the endothelial NO 
should undergo RHC and vasoreactivity test. For patients who 
have a positive vasoreactivity test, a trial of CCB therapy is recom-
mended. Patients who respond to such therapy should be reas-
sessed after 3–6 months of treatment. For patients who have a 
negative vasoreactivity test or fail CCB therapy, specific therapy 
with prostanoids, endothelin receptor antagonists, and phosphodi-
esterase 5 inhibitors is indicated. The preferred agent is related to 
the functional severity of the disease and the choice should also be 
done according to the physician experience, drug’s availability, and 
patient preference. For patients who are WHO functional class II, 
acceptable first-line agents include oral bosentan, oral sildenafil, 
oral ambrisentan. For patients who are WHO functional class III, 
acceptable first-line agents include oral bosentan, oral sildenafil, 
oral ambrisentan, inhaled iloprost, intravenous or subcutaneous 
treprostinil, intravenous epoprostenol. For patients who are WHO 
functional class IV intravenous epoprostenol has been suggested. 
An inadequate clinical response to a single agent represents an 
indication for a combination therapy. Finally, atrial septostomy 
and lung transplantation are reserved for patients refractory to 
medical therapy.
goal-orienTeD TheraPy
This approach concerns patients with PAH in whom the objec-
tive of treatment is to reduce functional impairment and pro-
long life (Sitbon and Galiè, 2010). Goal-oriented therapy uses 
known prognostic indicators as treatment targets thus facili-
tating  early  intervention  and  therapeutic  escalation  before 
patients deteriorate. A crucial role in this strategy is played by 
the identification of parameters that correlate with the risk of 
deterioration and mortality. Several data indicate that WHO 
FIGure 2 | Therapeutic approach for pulmonary arterial hypertension (PAH) based on the WHO functional class. CCB, calcium channel blocker.
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riociguaT
As well known, NO synthetized by eNOS is a potent vasodilator and 
is considered to play an important role in regulating pulmonary 
vascular tone. The downstream effector of NO is soluble guanylate 
cyclase (sGC), which synthetizes the secondary messenger cGMP. 
Increased levels of cGMP result in acute vasodilatation and reduction 
in platelet aggregation. Its chronic effects are prevention of the pul-
monary vascular remodeling as well as reduction in the RV afterload.
An animal model study conducted on mice with PAH induced 
by chronic hypoxia and rats with PAH induced by MCT, showed 
that both the sGC stimulator “Bay 41-2272” and sGC activator “Bay 
58-2667” could reverse PH and pulmonary vascular remodeling 
(Figure 5; Dumitrascu et al., 2006).
Riociguat is an oral stimulator of the NO receptor sCG which 
has demonstrated vasodilatory and antiremodeling properties in 
preclinical studies (Ghofrani and Grimminger, 2009).
A recent phase II trial is the first report that evaluated safety, toler-
ability and efficacy of riociguat on patients with moderate to severe 
PH of different etiology (PAH, CTEPH, PH due to interstizial lung 
disease; Grimminger et al., 2009). Riociguat had a favorable safety 
profile at single dose ≤ 2.5 mg. It was well tolerated and significantly 
improved pulmonary hemodynamic parameters measured by RHC 
in a dose dependent manner and to a greater extent than inhaled 
NO. Although riociguat had also systemic effects and showed no pul-
monary selectivity, mean systolic pressure remained > 110 mmHg.
Further  investigations  are  necessary  but  riociguat  can  be 
  considered an emerging option in PH therapy, included in patients 
with CTEPH (Kim, 2010).
synthase (eNOS) and a lower migration of inflammatory cells 
have been shown when Rho-kinase is inhibited (Fukumoto et al., 
2007).
A  recent  clinical  study  showed  a  Rho-kinase  activation  in 
patients with PAH (Do et al., 2009). Rho-kinase activity in cir-
culating neutrophils was significantly increased in PAH patients 
compared with controls. Analogously, the expression and activity 
of Rho-kinase in isolated lung tissues were significantly increased 
in PAH patients compared with controls. Finally, significant cor-
relations were noted between Rho-kinase activity and the severity 
and duration of PAH (Do et al., 2009).
In animal models, the treatment with Rho-kinase inhibitors 
seems to improve the endothelium dysfunction enhancing eNOS 
expression, suppressing hypercontraction and proliferation of the 
vascular smooth muscle cells and reducing the migration of inflam-
matory cells (Fukumoto et al., 2007).
A more recent study compared fasudil, a potent and selective 
Rho-kinase inhibitor, to bosentan and sildenafil in a rat model of 
monocrotaline (MCT) induced PAH (Mouchaers et al., 2010). Both 
fasudil in monotheraphy and fasudil in association with sildenafil 
or bosentan preserved heart rate, stroke volume and RV contrac-
tility, and reduced pulmonary vascular resistance and RV dilata-
tion. Fasudil significantly lowered PAPm by reducing pulmonary 
vascular remodeling and RV hypertrophy. Combining bosentan or 
sildenafil with fasudil had no synergistic effects (Mouchaers et al., 
2010). These results suggest that Rho-kinase inhibitors might be a 
novel therapeutic agent in PAH. A schematic representation of the 
mechanisms of pulmonary dilatation in response to some specific 
drugs and Rho-kinase inhibitors is illustrated in Figure 4.
FIGure 3 | Goal-oriented treatment algorithm for patients with pulmonary arterial hypertension (PAH). 6MWD, 6-min walking distance. Reproduced with 
permission from Hoeper et al. (2005).
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arterial hypertension (PAH). The sGC stimulator Bay41-2272 and the activator 
Bay58-2667 increase cGMP production, thereby regulating smooth muscle 
function. Bay41-2272 is an NO-dependent stimulator acting preferentially on the 
physiological form of sGC containing the iron II heme [Fe(II) heme] (left). In 
contrast, Bay58-2667 is a NO-independent activator preferably addressing the 
oxidized (and therefore NO-insensitive) iron III heme form [Fe(III) heme] of sGC 
(right). Increased levels of cGMP then result acutely in vasodilatation and 
antiaggregation and result chronically in antiremodeling of the vascular wall as 
well as unloading of the right ventricle. cGMP , cyclic guanosine monophosphate; 
GTP , guanosine triphosphate; NO, nitric oxide; Ox. stress, oxidative stress; RV, 
right ventricle. Reproduced with permission from Dumitrascu et al. (2006).
FIGure 4 | Mechanism of pulmonary dilatation in response to some specific 
drugs and rho-kinase inhibitors. 5-HT , serotonin; CaM, calmodulin; CCBs, calcium 
channel blockers; ET-1, endothelin-1; MLCK, myosin light chain kinase; MLCPh, 
myosin light chain phosphatase; NO, nitric oxide; PDE-5, phosphodiesterase-5; 
VSMC, vascular smooth muscle cell; PGI2, prostacyclin; PLC, phospholipase C; SR, 
sarcoplasmic reticulum. Reproduced with permission from Fukumoto et al. (2007).
seroTonin anTagonisTs
In the 1960s, serotonin was associated with PAH caused by certain 
diet pills (anorexigenic drugs aminorex and dexfenfluramine), but, 
more recently, it has been the subject of a renewed interest in the 
field of PAH (MacLean and Dempsie, 2010). Serotonin can be syn-
thetized in the pulmonary endothelium with the rate-limiting step 
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cAMP and increased proliferation of pulmonary vascular smooth 
muscle cells in patients with PH. Therefore, PDE1 isoforms may 
provide novel targets for the treatment of both idiopathic PAH 
and secondary PH.
vasoacTive inTesTinal PePTiDe (viP)
A further new concept for treatment of PH is based on VIP, a neu-
ropeptide primarily functioning as a neurotransmitter that acts as a 
potent systemic and pulmonary vasodilator. Rationale for the use of 
VIP is the finding of a deficiency of this peptide in serum and lung 
tissue of patients with idiopathic PAH with an upregulation of the 
corresponding receptor sites (Petkov et al., 2003). Consequently, the 
use of VIP results in a substantial improvement of hemodynamic 
parameters without significant side effects. It has been shown that 
VIP decreased PAPm in eight patients, increased CO and mixed 
venous oxygen saturation (Petkov et al., 2003). These data provide 
enough proof for further investigation of VIP as a novel therapy 
in idiopathic PAH.
conclusion
Current available drugs improve exercise capacity and functional 
class in patients with PH. Randomized trials have also shown 
improvement in hemodynamic parameters and time to clinical 
worsening. Although the impact on mortality has been less well 
established, advances in therapeutic strategies have allowed a better 
prognosis especially for patients with PAH. It is likely that com-
bination therapy will be the cornerstone of PAH treatment in the 
future and some novel agents will become part of the therapeutic 
armamentarium to improve the quality of life, slow the progression 
of disease and improve survival. Future directions are oriented to 
better elucidate the pathogenesis of PAH which remains incom-
pletely understood. Indeed, pathophysiology and genetics of this 
disease can represent a link to new treatments. Although it is clear 
that platelets, fibroblasts, and circulating cells are involved in the 
progression of PAH, changes in pulmonary arterial smooth mus-
cle cells and in pulmonary arterial endothelial cells resulting from 
multiple genetic and acquired defects are probably the major cause 
for the onset of the disease (Yuan and Rubin, 2005). Accordingly, 
efforts directed at developing effective therapeutic strategies should 
target genes, molecular mechanisms, and pathogenetic pathways 
involved in the disease.
being the activity of the tryptophan hydroxylase1 (Tph1). Then 
it can pass into the underlying pulmonary smooth muscle cells 
through the serotonin transporter (SERT) to initiate proliferation 
and/or it can activate serotonin receptors on pulmonary smooth 
muscle cells to evoke proliferation and/or contraction. Serotonin 
may  also  mediate  pulmonary  fibroblast  proliferation  via  the 
SERT and/or serotonin receptors. This is the basis of the so called 
“serotonin hypothesis” of PAH (MacLean, 2007). The activity of 
serotonin receptors, SERT and Tph1 can all be elevated in clinical 
and experimental PAH and each offers a potentially unique thera-
peutic target. Both serotonin receptor antagonists and serotonin-
transporter inhibitors are currently under consideration in order 
to verify the relevance of this new therapeutic strategy specifically 
directed against vascular proliferation.
PhosPhoDiesTerase-1 inhibiTors
PH is associated with increased vascular resistance due to sustained 
contraction and enhanced proliferation of pulmonary vascular 
smooth muscle cells. The abnormal tone and remodeling in the pul-
monary vasculature may relate, at least in part, to decreased cyclic 
nucleotide levels. Cyclic nucleotide phosphodiesterases (PDEs) 
catalyze the hydrolysis of both cyclic adenosine monophosphate 
(cAMP) and cGMP. Several studies analyzed the hypothesis that 
pulmonary vascular smooth muscle cells isolated from patients with 
either idiopathic PAH or secondary PH increased expression and 
activity of PDE isoforms so reducing the responsiveness to agents 
that raise cellular cAMP. It has been demonstrated that the expres-
sion of several families of PDE was enhanced in pulmonary vascular 
smooth muscle cells of patients with PH compared with controls 
(Murray et al., 2007). Consistent with this enhanced expression of 
PDEs, agonist-stimulated cAMP levels were significantly reduced 
in pulmonary vascular smooth muscle cells of both idiopathic PAH 
and secondary PH unless a PDE inhibitor was present. The use of 
specific PDE inhibitors revealed that an increase in PDE1 and PDE3 
activity largely accounted for reduced agonist-induced cAMP levels 
and increased proliferation in pulmonary vascular smooth mus-
cle cells. Treatment with PDE1C-targeted small interference RNA 
enhanced cAMP accumulation and inhibited cellular proliferation 
to a greater extent in pulmonary vascular smooth muscle cells of 
patients with PH than of controls. The results imply that an increase 
in PDE isoforms, in particular PDE1C, contributes to decreased 
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